This case highlights the significance of considering malignancy-associated antigen changes when interpreting ABO blood grouping, emphasizing the necessity for accurate typing methodologies and comprehensive transfusion management strategies in patients with PCM. The gene discussed is ABO; the disease is paracoccidioidomycosis.